DURAVELO Trademark

Trademark Overview


On Monday, December 4, 2023, a trademark application was filed for DURAVELO with the United States Patent and Trademark Office. The USPTO has given the DURAVELO trademark a serial number of 79387355. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, January 29, 2025. This trademark is owned by Bicycletx Limited. The DURAVELO trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical products, namely, pharmaceutical preparations for use in oncology; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology for the treatment of both solid and liquid tumors; pharmaceutical preparations for the treatment of urological and renal diseases; pharmaceutical preparations for the treatment of solid mass cancers, namely, bladder and urothelial cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, ovarian cancer, esophageal cancer, prostate cancer, cervical cancer, breast cancer, penile and anal cancer, gastric cancer, and colorectal cancer; pharmaceutical preparations for use as diagnostics, namely, diagnostic preparations for medical use and for use as clinical imaging agents

Medical research services, namely, scientific, clinical, and pharmacological medical research services; scientific research for medical purposes in the field of cancerous diseases; scientific and technological services, namely, scientific research and analysis and providing scientific research information in the field of oncology for both solid and liquid tumors, urological and renal diseases, and the treatment of solid mass cancers, namely, bladder and urothelial cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, ovarian cancer, esophageal cancer, prostate cancer, cervical cancer, breast cancer, penile and anal cancer, gastric cancer, and colorectal cancer; medical and scientific research, namely, conducting clinical trials for others; medical research, namely, conducting medical trials; providing of medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research in the field of oncology
duravelo

General Information


Serial Number79387355
Word MarkDURAVELO
Filing DateMonday, December 4, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateWednesday, January 29, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 18, 2025

Trademark Statements


Goods and ServicesPharmaceutical products, namely, pharmaceutical preparations for use in oncology; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology for the treatment of both solid and liquid tumors; pharmaceutical preparations for the treatment of urological and renal diseases; pharmaceutical preparations for the treatment of solid mass cancers, namely, bladder and urothelial cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, ovarian cancer, esophageal cancer, prostate cancer, cervical cancer, breast cancer, penile and anal cancer, gastric cancer, and colorectal cancer; pharmaceutical preparations for use as diagnostics, namely, diagnostic preparations for medical use and for use as clinical imaging agents
Goods and ServicesMedical research services, namely, scientific, clinical, and pharmacological medical research services; scientific research for medical purposes in the field of cancerous diseases; scientific and technological services, namely, scientific research and analysis and providing scientific research information in the field of oncology for both solid and liquid tumors, urological and renal diseases, and the treatment of solid mass cancers, namely, bladder and urothelial cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, ovarian cancer, esophageal cancer, prostate cancer, cervical cancer, breast cancer, penile and anal cancer, gastric cancer, and colorectal cancer; medical and scientific research, namely, conducting clinical trials for others; medical research, namely, conducting medical trials; providing of medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research in the field of oncology

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 12, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 12, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBicycletx Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Thursday, January 11, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, January 16, 2024APPLICATION FILING RECEIPT MAILED
Tuesday, July 9, 2024NON-FINAL ACTION WRITTEN
Wednesday, July 31, 2024REFUSAL PROCESSED BY MPU
Sunday, August 25, 2024REFUSAL PROCESSED BY IB
Friday, January 12, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 1, 2024ASSIGNED TO EXAMINER
Wednesday, July 10, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, July 31, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, January 9, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 9, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 9, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 28, 2025APPROVED FOR PUB - PRINCIPAL REGISTER